Quantcast
Home > Quotes > SBPH

Spring Bank Pharmaceuticals, Inc. Common Stock (SBPH) Quote & Summary Data

SBPH 
$4.59
*  
0.12
2.55%
Get SBPH Alerts
*Delayed - data as of Jun. 14, 2019  -  Find a broker to begin trading SBPH now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
25
Today's High / Low
$ 4.80 / $ 4.50
Share Volume
54,120
50 Day Avg. Daily Volume
72,781
Previous Close
$ 4.71
52 Week High / Low
$ 15 / $ 4.51
Market Cap
75,473,976
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.48

Intraday Chart

Shares Traded

Share Volume:
54,120
50 Day Avg. Daily Volume:
72,781

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.53

Trading Range

The current last sale of $4.59 is 1.77% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 4.80 $ 15
 Low: $ 4.50 $ 4.51

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers using our proprietary small molecule nucleotide platform. We design our compounds to selectively target and modulate the activity of specific proteins implicated in various disease states. We are developing our lead product candidate, inarigivir soproxil, or inarigivir, for the treatment of chronic hepatitis B virus, or HBV. We have designed our antiviral product candidates, including inarigivir, to selectively activate within infected hepatic cells the cellular protein, retinoic acid-inducible gene 1 (RIG-I), to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense.  ... More ...  



Risk Grade

Where does SBPH fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 4.70
Open Date:
Jun. 14, 2019
Close Price:
$ 4.59
Close Date:
Jun. 14, 2019


Consensus Recommendation

Analyst Info